Business
Doctor's Best Celebrates FDA Decision on NMN Supplements, Relaunches Product Line
Doctor's Best, a leading nutritional supplement company, announces that its parent company, Xiamen Kingdomway Group, has received a New Dietary Ingredient (NDI) letter from the Food and Drug Administration (FDA) for its beta-Nicotinamide Mononucleotide (NMN) supplements. This FDA action permits the sale of NMN products by Kingdomway and marks a pivotal moment for the company and the broader supplement market.
About this update from Xiamen Kingdomway Group Co. Class A
[{"type":"text","content":"Parent Company of Doctor's Best Secures Coveted NDI Letter for NMN Supplement Sales","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"TUSTIN, Calif., Jan. 7, 2026 /PRNewswire/ -- Doctor's Best, a leading nutritional supplement company, announces that its parent company, Xiamen Kingdomway Group, has received a New Dietary Ingredient (NDI) letter from the Food and Drug Administration (FDA) for its beta-Nicotinamide Mononucleotide (NMN) supplements. This FDA action permits the sale of NMN products by Kingdomway and marks a pivotal moment for the company and the broader supplement market.","length":471,"tagName":"p"},{"type":"image","alt":"Doctor's Best currently offers three NMN formulations: NMN + Coq10 (150 mg), NMN+ (200 mg), and NMN Delayed Release (400 mg).","displaySize":"","headline":null,"caption":"Doctor's Best currently offers three NMN formulations: NMN + Coq10 (150 mg), NMN+ (200 mg), and NMN Delayed Release (400 mg).","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":325,"url":"https://media.zenfs.com/en/prnewswire.com/b48660499b29e51f32eb6dcb83040b06"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7AcM7l.TA6PgDH2JNo23Hw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b48660499b29e51f32eb6dcb83040b06","width":400,"height":325}},"href":"https://mma.prnewswire.com/media/2855966/Doctors_Best_currently_offers_three_NMN_formulations.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We applaud the FDA's decision reaffirming that NMN is lawful and safe for use in dietary supplements," said David Jiang, Chairman of Xiamen Kingdomway Group. "Our NDI recognition marks an important achievement for Kingdomway and reflects our dedication to new ingredient research and development, regulatory compliance, and ingredient efficacy across the industry."","length":390,"tagName":"p"},{"type":"text","content":"Key highlights of the FDA's decision include:","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Authorization for the sale of beta-Nicotinamide Mononucleotide (NMN) in dietary supplements","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Reversal of a prior regulatory interpretation that had restricted NMN'...